Matt Segall: Difference between revisions

From Crucible Network Research Projects
Jump to navigationJump to search
No edit summary
No edit summary
 
Line 1: Line 1:
Founder of Optibrium, previously at ArQule, Matt commissioned a Crucible team to develop new [[design approaches to drug discovery]] that exploited quantum mechanical modelling techniques to optimise drug discovery processes through in silico simulation of compounds before they were synthesised.
Founder of Optibrium, previously at ArQule, Matt commissioned a Crucible team to develop new [[design approaches to drug discovery]] that exploited quantum mechanical modelling techniques to optimise drug discovery processes through in silico simulation of compounds before they were synthesised.
[[Category:People]]

Latest revision as of 06:24, 26 August 2011

Founder of Optibrium, previously at ArQule, Matt commissioned a Crucible team to develop new design approaches to drug discovery that exploited quantum mechanical modelling techniques to optimise drug discovery processes through in silico simulation of compounds before they were synthesised.